MedTrace Logo

Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

NCT07419932 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2026-02-19

No results posted yet for this study

Summary

This multicenter observational study aims to evaluate the safety and efficacy of neoadjuvant therapy in patients with locally advanced thyroid cancer, focusing on imaging, biochemical, and pathological responses, as well as short-term surgical outcomes and long-term prognosis.

Conditions

Interventions

DRUG

Multitarget Tyrosine Kinase Inhibitors

Patients with or without actionable genomic alterations may receive a multikinase inhibitor (e.g., lenvatinib or anlotinib) as neoadjuvant therapy.

DRUG

BRAF inhibitor dabrafenib and MEK inhibitor trametinib

Patients with BRAF V600E mutation may receive combination therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib.

DRUG

RET Inhibitor

Patients with RET fusion may receive a selective RET inhibitor (e.g., selpercatinib).

DRUG

PD(L)-1 inhibitor

In selected cases, combination regimens incorporating immunotherapy may be considered.

PROCEDURE

Biopsy

While fine-needle aspiration (FNA) is the standard initial diagnostic modality for thyroid nodules, core needle biopsy (CNB) is performed to obtain tissue cores for histological subtyping and molecular profiling in locally advanced cases.

PROCEDURE

Surgery

Patients considered resectable after neoadjuvant therapy will undergo definitive surgery, as determined by consensus of the multidisciplinary team (MDT).

PROCEDURE

Surgery

Patients deemed resectable at baseline will undergo immediate surgery based on MDT consensus and informed patient preference.

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-23
Primary Completion
2028-12-31
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07419932 on ClinicalTrials.gov